Thymosin Alpha 1 Boosts Long-Term Survival in Lung Cancer Patients Post-Surgery
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths globally, and even after successful R0 resection (complete surgical removal of all visible tumor), patients face a significant risk of recurrence and mortality. While surgery is curative for many, there remains a critical need for effective adjuvant therapies to improve long-term outcomes. This study specifically addresses whether immunomodulatory therapy with thymosin α1 can enhance long-term survival rates in NSCLC patients after R0 resection.
Results
The study revealed a significant improvement in long-term survival for patients treated with thymosin α1. The 5-year overall survival (OS) rate was 73.4% in the thymosin α1 group compared to 66.1% in the control group, representing a 7.3 percentage point increase. Similarly, the 5-year disease-free survival (DFS) rate was 68.2% for thymosin α1 recipients versus 59.3% for controls. Treatment with thymosin α1 significantly reduced the risk of death by 30%, with a hazard ratio (HR) of 0.70 (p=0.001), and lowered the risk of disease recurrence or death by 27% (HR = 0.73, p=0.002). Subgroup analyses further indicated that the benefits of thymosin α1 were consistent across various disease stages, including stage IB, IIA, IIB, and IIIA NSCLC.
Why It Matters
This research highlights the significant potential of thymosin α1, an immunomodulatory peptide, to improve long-term survival and reduce recurrence in non-small cell lung cancer patients following curative surgery. The observed 7.3 percentage point increase in 5-year overall survival is clinically meaningful, suggesting that thymosin α1 could serve as a valuable adjuvant therapy. These findings strongly support the initiation of prospective, randomized controlled trials to confirm its efficacy and establish optimal dosing regimens for clinical use. If validated, thymosin α1 could become a standard component of post-surgical care for NSCLC patients.